Mr. Speaker, again, I agree with the Auditor General's recommendations on the department in strengthening its approach to clinical trials. New procedures are being put in place to improve transparency, and to better monitor clinical trials and adverse reaction reports.
To strengthen the pharmaceutical drug program, a new IT system has also been put in place to help better identify potential safety concerns. The audit is from 2009-10, so we have acted on a number of the recommendations already.